Skip to main
DOCS

Doximity (DOCS) Stock Forecast & Price Target

Doximity (DOCS) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 24%
Buy 24%
Hold 48%
Sell 5%
Strong Sell 0%

Bulls say

Doximity is set to experience continued growth from its existing customer base and new hires in chief roles as demonstrated by the recent appointment of Matt Sonefeldt and Dr. Steve Zatz. However, challenges may arise with a decline in marketing spend from pharmaceutical companies due to a decreasing number of drugs under patent protection. Additionally, the company's F2027E guidance is lower than expected, with modest market growth and shorter-term spend commitments from customers due to macroeconomic concerns.

Bears say

Doximity is a promising digital health platform with recent successful partnerships and expansion efforts. However, their growth potential is hindered by market conditions and limited visibility into customer budgets, which has led analysts to lower revenue and EBITDA estimates. As a result, the company has been downgraded to Neutral and faces competition from other healthcare software companies like Veeva. Doximity and Veeva both face risks in retaining and attracting customers, which could affect their future growth prospects.

Doximity (DOCS) has been analyzed by 21 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 24% recommend Buy, 48% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Doximity (DOCS) Forecast

Analysts have given Doximity (DOCS) a Buy based on their latest research and market trends.

According to 21 analysts, Doximity (DOCS) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Doximity (DOCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.